Antibody for DNA Degradation
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
Inflammatory bowel disease, cystic fibrosis, and arthritis; promoting DNA degradation to diminish inflammation via DNase1L3 enhancement
Modality
Monoclonal Antibody
Mechanism
DNase1L3-enhancing autoantibody
Target
DNase1L3
rNPV Envelope
Low
-$50.2M
costs +25% · peak −25%
Base
-$35.6M
cumulative PoS 1.8%
High
-$21.1M
costs −25% · peak +25%
Costs follow biologic CMC/clinical norms with an elevated, elongated preclinical stage because the asset is at in vitro single-clone stage with no in vivo data and an autoantibody-as-drug developability path that is unprecedented (humanization, immunogenicity, non-nephritogenicity must all be re-confirmed). Phase 2 PoS is held well below RA/SLE-mAb baselines because the enhancing mechanism rests on one hypothesis-generating clone (32.B9, Hartl 2023) and lupus Phase 2 attrition is historically severe; Phase 3 reflects mixed SLE confirmatory-trial precedent partially de-risked if a cf-DNA-clearance pharmacodynamic biomarker translates. Cumulative LoA ≈ 1.8%, appropriately lower than the hand-validated top-10 6–11% band given the earlier, mechanism-unproven stage.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.60
Modality fit · 30%
0.90
Whitespace · 30%
0.50
Composite 0.660 — composite-score rank #12 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#27) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
NTR-441 / NTR-1011 (Neutrolis) — albumin-DNASE1L3 fusion enzyme replacement
Closest mechanism-true competitor: same molecular target (DNASE1L3) and identical therapeutic goal — restore DNASE1L3-mediated degradation of cell-free DNA / NETs to resolve autoimmune inflammation. NTR-441 completed a Phase 1 with first-in-human proof-of-concept (ACR Convergence 2025) showing multi-organ improvement within 6 hours in a DNASE1L3-deficient SLE patient; lead NTR-1011 (subcutaneous, exDNASE platform) has Phase 2a in SLE AND RA planned for 2026. Reads the same biology by the enzyme-replacement route rather than the JHU asset's enhancing-autoantibody route, and is materially further along, defining the competitive bar and the SLE/RA development pathway.
Criteria 1 and 2: same target (DNASE1L3) and same therapeutic mechanism (restore cf-DNA/NET clearance) in the same indications (SLE, RA); clinical-stage so it anchors stage cost/duration and the regulatory pathway for a DNASE1L3-restoring agent.
1833 / LBme dual-acting DNASE1·DNASE1L3 enzyme biologic (Yale, Braddock lab — Yale–Johns Hopkins collaboration)
Mechanism-class academic comparator validating that cf-DNA / NET degradation prevents autoimmunity and death: weekly dosing prevented all lupus autoantibodies over 40 weeks in Dnase1−/−Dnase1L3−/− double-knockout mice and reduced mortality after pristane acceleration (~15% vs ~50% deaths); therapeutic dosing in induced lupus raised survival to 95% vs 70% (JCI Insight 2024). Preclinical, enzyme-replacement modality — confirms the target/mechanism is being actively pursued by multiple groups via the enzyme route, framing the competitive landscape the JHU enhancing-antibody approach would enter.
Criteria 1: same target/mechanism class (DNASE1L3-mediated cf-DNA degradation as lupus therapy). Preclinical mechanism-identical comparator anchoring in vivo proof-of-mechanism expectations and the crowded enzyme-route IP/timing landscape.
Pulmozyme (Genentech/Roche) — dornase alfa, recombinant human DNase I
Only launched precedent for degrading extracellular DNA as a therapy, and in cystic fibrosis — an indication the JHU invention explicitly names. Establishes that an extracellular-DNA-degrading biologic can be approved and durably commercialized (~CHF 455M / ~$500M 2024 Roche sales). Different modality (inhaled recombinant enzyme for CF airway mucus, not a systemic enhancing autoantibody for autoimmune cf-DNA) so it bounds the regulatory pathway and a niche-population revenue floor, not the SLE/RA economics.
Criteria 2 and 3: launched extracellular-DNA-degrading biologic in a JHU-named indication (CF); anchors regulatory feasibility of a DNA-degrading agent and a durable niche-population revenue floor.
Benlysta (GSK) — belimumab, anti-BLyS monoclonal antibody
Economic ceiling anchor for a successful SLE monoclonal antibody: £1.49B (~$1.9B) FY2024 sales, +14%, with ~62% biologic-treated SLE patient share. Different mechanism (BLyS/B-cell axis, not cf-DNA clearance) so it is a market-size and SLE-biologic-launch anchor, not a mechanism comparator; it sets the realistic blockbuster upper bound a cf-DNA-clearance mAb would have to displace standard of care to approach.
Criteria 2 and 4: launched SLE monoclonal-antibody comparator with comparable target patient population; anchors the SLE-biologic peak-revenue ceiling and standard-of-care displacement bar.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $22.0M | 30 mo | 30.0% | [0] [1] [2] |
| Phase I | $55.0M | 18 mo | 55.0% | [0] [4] |
| Phase II | $150.0M | 30 mo | 28.0% | [0] [1] [5] |
| Phase III | $320.0M | 42 mo | 45.0% | [0] [5] [6] |
| NDA/BLA Review | $16.0M | 12 mo | 85.0% | [6] [7] |
Multiplier handling: Eligible multipliers (genetic_validation_2.6x, biomarker_1.7x) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$650.0M peak · WACC 14.0%
Peak revenue. Benlysta (~$1.9B FY2024) sets the SLE-mAb blockbuster ceiling and Saphnelo (~$340–474M, growing) the mid-tier; Pulmozyme (~$500M) frames a durable but niche DNA-degrading-biologic floor. A successful DNASE1L3-enhancing antibody would launch into an SLE/RA market already served by belimumab, anifrolumab, anti-TNF and JAK agents, and ahead of it the further-along Neutrolis enzyme-replacement franchise; $650M reflects a realistic risk- and competition-discounted Year-7 share in a cf-DNA-biomarker-defined autoimmune subset, deliberately below Benlysta because the asset would enter as a later, mechanism-differentiated entrant against entrenched standard of care and a clinical-stage same-target competitor. For this partnership-archetype asset the Johns Hopkins owner would realistically capture royalties (mid-single to low-double digit) plus milestones on this peak, not the full product revenue.
WACC. An SLE/RA biologic is a mainstream pharma category (12% base), but the unprecedented enhancing-autoantibody mechanism, in vitro-only single-clone evidence, autoantibody developability risk, and a further-along same-target competitor push risk to 14%.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$35.6M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$157.0M
P25
-$48.1M
P50 (median)
-$20.9M
P75
-$12.7M
P95
-$6.1M
Prob ≥ 0
2.8%
Comparable launch curves
Revenue trajectories of named comparators
Pulmozyme (Genentech/Roche) — dornase alfa, recombinant human DNase I
Launched 1993 · peak $475.0M (estimated)
Evidence register
8 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
Asset identity, in vitro-only stage, named indications, and supporting publication cmo_findings.asset_class_reality | Antibody for DNA Degradation — Johns Hopkins Technology Ventures technology listing (Case C17773) regulatory | 2023-11-29 | high |
Enhancing activity rests on a single clone the original authors flagged as surprising and hypothetical (mechanism/data-provenance risk) stage_profile.preclinical.pos | Affinity maturation generates pathogenic antibodies with dual reactivity to DNase1L3 and dsDNA in systemic lupus erythematosus (Hartl et al., Nat Commun 2023) peer_review | 2023-03-20 | high |
Same-target clinical-stage competitor (Neutrolis NTR-441/NTR-1011) defines pathway, Phase-2 bar, and SLE+RA indications comparators[0] | Neutrolis Presented First-in-Human Proof-of-Concept Data Validating DNASE1L3-Mediated NET Clearance as a Therapeutic Approach in Autoimmunity at ACR Convergence 2025 news | 2025-10-29 | high |
NTR-441 first-in-human SLE proof-of-concept and cf-DNA pharmacodynamic readout stage_profile.phase_2.pos | Early Evidence of Proof-of-Concept of an Albumin-DNASE1L3 Fusion Protein (NTR-441) for the Rapid Enzymatic Inactivation of NETs in SLE with DNASE1L3-Deficiency (ACR Meeting Abstracts) trial_disclosure | 2025-10-01 | high |
Mechanism-class in vivo proof: cf-DNA/NET degradation prevents autoimmunity and death in lupus models (competitive landscape) comparators[1] | A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models (JCI Insight 2024) peer_review | 2024-06-24 | high |
Mendelian DNASE1L3 loss-of-function causes SLE/HUV with high arthritis frequency (target genetic validation and RA-tag basis) multipliers_rationale | DNASE1L3 Mutations in Hypocomplementemic Urticarial Vasculitis Syndrome (Ozcakar et al., Arthritis Rheum 2013) peer_review | 2013-07-01 | high |
SLE monoclonal-antibody blockbuster ceiling for peak-revenue anchoring peak_revenue_usd | GSK FY2024 Results Announcement (Benlysta full-year sales) company_filing | 2025-02-12 | high |
Launched extracellular-DNA-degrading biologic regulatory precedent (CF) comparators[2] | PULMOZYME (dornase alfa) FDA label — Genentech (DailyMed) regulatory | 2021-01-01 | high |
Thesis
Why this asset earns its rank
This is an early-stage therapeutic-antibody concept, not a de-risked drug. Johns Hopkins investigators identified an anti-dsDNA autoantibody that, instead of neutralizing the endonuclease DNASE1L3, associates with it and enhances degradation of extracellular (cell-free) DNA — and, critically, is reported to be non-nephritogenic, avoiding the lupus-nephritis liability of pathogenic anti-dsDNA antibodies. The target biology is strongly human-validated: biallelic DNASE1L3 loss-of-function is a Mendelian cause of monogenic SLE and hypocomplementemic urticarial vasculitis, with arthritis in ~82% of patients, which is what maps this asset to the rheumatoid_arthritis bucket and underwrites the premise that restoring DNASE1L3 activity is disease-modifying. The candor a CMO will demand: the enhancing activity rests on a single clone (32.B9) from the Hartl 2023 Nature Communications paper, whose dominant finding is that anti-DNASE1L3 antibodies are pathogenic and neutralizing; the authors themselves called 32.B9's chromatin-degradation enhancement "surprising" and "a hypothesis that will need further exploration," with no proposed mechanism and no in vivo data. The asset is at in vitro single-clone stage.
The economic frame is set by mechanism-true competitors that are materially further along. Neutrolis's albumin-DNASE1L3 fusion (NTR-441, Phase 1 first-in-human proof-of-concept at ACR 2025; lead NTR-1011 with Phase 2a in SLE and RA planned 2026) pursues the identical therapeutic goal by enzyme replacement, and the Yale–Hopkins dual-acting DNASE1/DNASE1L3 biologic showed strong in vivo survival benefit in lupus models — so the JHU enhancing-antibody approach enters a landscape where the enzyme route is already in the clinic and the bar is being defined by others. Pulmozyme proves an extracellular-DNA-degrading biologic can be approved and durably commercialized (~$500M, niche CF), while Benlysta (~$1.9B FY2024) bounds the SLE-mAb blockbuster ceiling a cf-DNA-clearance agent would have to displace standard of care to approach. The engine result is -$50.2M to -$21.1M, with a base rNPV of -$35.6M and cumulative PoS of 1.8%; that spread reflects a real target with weak asset-stage evidence and a clinical-stage same-target competitor, which is why standalone VC equity is not the honest archetype here.
Verdict: a mechanistically interesting, genetically well-validated target attached to a very early, single-clone, mechanism-unproven antibody facing a further-along competitor — a partnership/licensing candidate, not a standalone VC raise. It earns its rank on clinical relevance (a credible cf-DNA-clearance mechanism in serious autoimmune disease) and a high modality_pos for the antibody bucket, not on being a fundable product; the funding-path archetype is partnership_candidate because the value path is co-development or licensing to a group that can fund in vivo validation and compete with the enzyme-replacement programs, with Johns Hopkins capturing royalties and milestones rather than full product economics.
Key risks
Asset-specific, not generic biotech risks
- Data-provenance / mechanism risk: the entire therapeutic premise rests on one clone (32.B9) whose enhancement of DNASE1L3-mediated chromatin degradation was an incidental, mechanism-unexplained observation in a paper whose main finding is that anti-DNASE1L3 antibodies are pathogenic and neutralizing; the authors explicitly framed it as a hypothesis needing further exploration. No in vivo data exist yet.
- Modality-bucket vs reality: the pinned bucket is monoclonal_antibody, but functionally this is an enzyme-enhancing / substrate-presenting effector autoantibody with no marketed precedent for the mechanism; the closest mechanism-true comparators (Neutrolis NTR-441/NTR-1011, Yale 1833) are engineered enzyme-replacement biologics, not therapeutic mAbs, so conventional mAb developability and PoS priors may not transfer.
- Competitive timing: Neutrolis is already in the clinic against the same target with first-in-human SLE proof-of-concept and Phase 2a in SLE and RA planned for 2026; an in-vitro-stage antibody is years behind and risks being a second-best mechanism if enzyme replacement establishes efficacy and safety first.
- Autoantibody-as-drug safety: deliberately developing an anti-dsDNA autoantibody as a therapeutic carries non-trivial immune-complex and nephritogenicity risk; the 'non-nephritogenic' claim is based on limited in vitro/early data and must be re-confirmed through humanization and clinical testing before it can be relied upon.
- Indication framing: the rheumatoid_arthritis tag is a JHTV taxonomy mapping (the invention's lead-described indications are SLE, cystic fibrosis, IBD, asthma, sepsis); the RA path is defensible only via the DNASE1L3-deficiency arthritis phenotype and Neutrolis's planned RA Phase 2a, and SLE/RA are non-orphan markets so orphan/expedited-pathway economics do not apply outside the rare DNASE1L3-deficient subset.